Virus therapy with chemo and immunotherapy for advanced lung cancer
Treatments studied
Part of Cancer, Infections, Lungs & breathing clinical trials.
This trial tests a new treatment that uses a virus to attack cancer cells, combined with standard chemotherapy and an immunotherapy drug, for people with advanced non-small cell lung cancer that has gotten worse after initial treatment. The goal is to see if this combination works better than a different chemotherapy drug alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced or metastatic non-small cell lung cancer (stage III or IV).
- You received at least 2 cycles of platinum-based chemo plus an immunotherapy drug as your first treatment, but your cancer started growing again.
- You have at least one tumor that can be measured on a CT or MRI scan, not in the brain.
- You are able to take care of yourself (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
This trial tests a three-drug combination (ipilimumab, nivolumab, and nogapendekin alfa inbakicept) as a first treatment for people with stage IV or recurrent non-small cell lung cancer. The goal is to see if this approach can help your immune system fight the cancer more effectively.
This trial tests a new combination of drugs (visugromab, nivolumab, and possibly docetaxel) for people with advanced non-squamous non-small cell lung cancer that worsened after one prior treatment with an immunotherapy. The goal is to see if the combination helps control the cancer better.
This trial tests a combination of an immunotherapy drug (sintilimab) with chemotherapy to shrink advanced lung cancer that cannot be removed with surgery. The goal is to see if the cancer becomes operable after treatment and to improve outcomes.
This trial tests giving radiation and immunotherapy together to people with advanced lung cancer that hasn't been treated yet. The goal is to see if this combination can shrink tumors and help patients live longer.
Hear when a new Advanced Non-squamous Non-small-cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.